The Safety and Efficacy of 12 Versus 24 Hours of Tirofiban Infusion in Patients Undergoing Primary Percutaneous Coronary Intervention

Topcu S., Karal H., Kaya A., Bakirci E. M., Tanboga I. H., Kurt M., ...Daha Fazla

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, cilt.21, sa.8, ss.783-789, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Sayı: 8
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1177/1076029614529841
  • Dergi Adı: CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.783-789
  • Anahtar Kelimeler: tirofiban infusion, ST-segment elevation myocardial infarction, primary percutaneous, coronary intervention, IIB/IIIA RECEPTOR ANTAGONISTS, GLYCOPROTEIN IIB/IIIA, MYOCARDIAL-INFARCTION, DOUBLE-BLIND, METAANALYSIS, IMPLANTATION, EPTIFIBATIDE, INHIBITORS, ABCIXIMAB, PLACEBO
  • Atatürk Üniversitesi Adresli: Evet

Özet

Aim: We aimed to investigate the 6-month efficacy and safety of postprocedural 12-hour tirofiban administration versus 24-hour tirofiban administration in patients with ST-segment elevated myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI).